Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients With Neovascular AMD

Next Previous
Search
Trial Profile

A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients With Neovascular AMD

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Foselutoclax (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms ENVISION
  • Sponsors UNITY Biotechnology

Most Recent Events

  • 25 Apr 2024 According to an UNITY Biotechnology media release, data from this trial will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held on May 5-9, 2024 in Seattle, Washington.
  • 24 Oct 2023 Status changed from active, no longer recruiting to completed.
  • 27 Sep 2023 According to an UNITY Biotechnology media release, additional 48-week data from the ENVISION study is expected to be presented at upcoming medical conferences.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top